<DOC>
	<DOCNO>NCT00000792</DOCNO>
	<brief_summary>To determine safety tolerance daily oral hypericin give achieve target trough level within define cohort . To determine response surrogate marker HIV infection daily oral hypericin . It know whether daily oral dosing produce tolerable prolonged exposure therapeutic level hypericin . Pharmacokinetic modeling study demonstrate daily oral dosing produce trough level desire range without excessive peak level .</brief_summary>
	<brief_title>A Pharmacologically Guided Phase I/II Study Daily Orally Administered Synthetic Hypericin HIV-Infected Subjects</brief_title>
	<detailed_description>It know whether daily oral dosing produce tolerable prolonged exposure therapeutic level hypericin . Pharmacokinetic modeling study demonstrate daily oral dosing produce trough level desire range without excessive peak level . Cohorts six patient receive escalate dos oral hypericin daily . Blood sample peak trough level second week therapy . A computer model algorithm use level determine appropriate dose need patient achieve desire trough level . When three six patient give dose complete 3 week therapy without evidence dose-limiting toxicity , data review determine whether subsequent patient enter next high dose . The MTD define dose level immediately grade 3 bad toxicity see three six patient .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hypericin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : PCP prophylaxis . Allowed : Rifabutin , ketoconazole , fluconazole , acyclovir , provide medication take least 4 week prior study entry without toxicity . Topical medication clotrimazole troche nystatin suspension . Patients must : Documented HIV infection . CD4 count &lt; = 350 cells/mm3 . p24 antigen positive &gt; = 35 pcg/ml . No active opportunistic infection study entry would require curative suppressive therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancy systemic chemotherapy require . Medically significant liver disease , orthostatic hypotension , hypertension , cardiac disease , seizure disorder , lymphoma . Any medical condition would interfere evaluation patient . Concurrent Medication : Excluded : AZT , ddI , ddC , d4T , antiretroviral medication . Interferon immunomodulating drug . Cytotoxic chemotherapy . Foscarnet . Ganciclovir . Antimycobacterial drug rifabutin . MAO inhibitor . Hypertensioninducing , nephrotoxic , hepatotoxic drug . Opiates . Drugs know cause photosensitivity . Prior Medication : Excluded within 1 month prior study entry : AZT , ddI , ddC , d4T , antiretroviral medication . Interferon immunomodulating drug . Cytotoxic chemotherapy . Preparations know contain hypericin . Excluded within 3 month prior study entry : Ribavirin . Hyperforate ( 500 mg tablet ampules IV injection ) manufacture Kline . Psychotonin M Alcohol Extract manufacture Steigerwald . Hypericin ( 40 mg vial ) VIMRx . Excluded within 14 day prior study entry : Foscarnet . Ganciclovir . Antimycobacterial drug rifabutin . MAO inhibitor . Hypertensioninducing , nephrotoxic , hepatotoxic drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>